pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PD-1 · news · pharmadog
← back to PD-1
News · PD-1
40
stories
2h
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
7d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
9d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
9d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
9d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
15d
BMS picks Texas for new $2.3B manufacturing campus
biospace
16d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
19d
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
19d
Is the biotech capital of the world moving?
stat
19d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
19d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
19d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
21d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
22d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
22d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
23d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
26d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
26d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
28d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
29d
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
29d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
29d
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
← prev
page 1 of 2
next →
